NASDAQ · ETON
Healthcare · Biotechnology
$57.88
Up+$0.51 (+0.88%)
Updated Sep 11, 2026, 2:19 PM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ETON closed at $57.88 after 20 trading sessions, up 41.86% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $58.78 | $59.5518 | $57.6107 | $57.88 | 281.7K |
| Sep 9, 2026 | $58.91 | $60.43 | $58.66 | $58.83 | 373.71K |
| Sep 8, 2026 | $57.37 | $59.98 | $56.11 | $59.345 | 396.34K |
| Sep 4, 2026 | $59.87 | $59.945 | $56.93 | $58.45 | 521.6K |
| Sep 3, 2026 | $61.96 | $62.3899 | $59.70 | $59.90 | 497.56K |
| Sep 2, 2026 | $61.15 | $62.91 | $59.59 | $61.96 | 577.77K |
| Sep 1, 2026 | $60.41 | $61.7202 | $59.89 | $60.43 | 564.61K |
| Aug 31, 2026 | $59.04 | $60.61 | $58.24 | $60.44 | 768.01K |
| Aug 28, 2026 | $61.98 | $62.12 | $58.3265 | $59.78 | 588.75K |
| Aug 27, 2026 | $62.50 | $63.26 | $61.875 | $62.67 | 445.97K |
| Aug 26, 2026 | $63.60 | $63.60 | $61.03 | $62.62 | 443.5K |
| Aug 25, 2026 | $64.55 | $65.50 | $62.00 | $63.05 | 536.95K |
| Aug 24, 2026 | $63.90 | $66.37 | $62.90 | $64.43 | 801.54K |
| Aug 21, 2026 | $59.76 | $64.00 | $59.76 | $63.47 | 640.79K |
| Aug 20, 2026 | $60.99 | $62.58 | $59.59 | $59.91 | 586.53K |
| Aug 19, 2026 | $63.55 | $63.83 | $60.06 | $61.48 | 608.92K |
| Aug 18, 2026 | $61.10 | $63.5591 | $60.00 | $63.43 | 872.48K |
| Aug 17, 2026 | $59.15 | $62.87 | $56.65 | $61.73 | 1.28M |
| Aug 14, 2026 | $54.93 | $59.79 | $53.01 | $58.86 | 2.32M |
| Aug 13, 2026 | $42.11 | $43.19 | $40.66 | $40.80 | 696.94K |
The latest Smart Investors Daily articles mentioning ETON.
ETON research
Company profile and research snapshot.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | B. Riley Securities | Buy | — |
| Aug 14, 2026 | Canaccord Genuity | Buy | — |
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 28, 2026 | Craig-Hallum | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 1, 2026
A substantial insider activity was disclosed on August 31, as V, Board Member at Eton Pharmaceuticals (NASDAQ:ETON), reported the exercise of a large sell of company stock options. What Happened: A Form 4 filing with
Yahoo · Aug 28, 2026
During the lightning round of the August 26 Mad Money episode, a caller asked whether it is time to “cut it off” or if Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has more potential given that they bought the shares at $30 and the stock is now above $60. In response, Jim Cramer said: I think you take […]
Yahoo · Aug 27, 2026
DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your
Benzinga · Aug 27, 2026
Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on BillionToOne, and calls Eton Pharma a winner.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ETON.
